How to Prepare an IND Application: FDA Checklist | BioBoston

Preparing an Investigational New Drug application is one of the most important transitions in drug development. It is the point where years of scientific work must become a clear, reviewable argument that a proposed clinical study can proceed without exposing participants to unreasonable risk.

That makes IND preparation more than a document-assembly exercise. The nonclinical evidence, chemistry, manufacturing and controls information, starting-dose rationale, clinical protocol, investigator information and safety-monitoring plan must support the same development story. When these elements are produced in separate silos, inconsistencies often surface late, when they are more difficult and expensive to resolve.

This guide explains how to prepare an IND application, what FDA expects to see, how to organize the work, and which issues deserve attention before submission. If your program is already approaching a pre-IND meeting or filing milestone, BioBoston Consulting provides IND application consulting and FDA submission support tailored to your product, team and development stage.

What is an Investigational New Drug application?

An Investigational New Drug application, commonly called an IND, is the submission through which a sponsor asks FDA to allow an investigational drug or biological product to be used in a clinical investigation in the United States. FDA describes the IND as the mechanism that permits interstate shipment of an investigational product before it has an approved marketing application.

The immediate question during the initial review is not whether the product has been proven safe and effective for marketing. The central issue is whether the available information supports exposing participants to the investigational product under the conditions of the proposed clinical protocol. FDA's IND application overview explains the pathway, categories and core evidence areas.

It is also important to use precise language. FDA does not “approve” an IND in the same way that it approves a New Drug Application or Biologics License Application. Under 21 CFR 312.40, an IND generally goes into effect 30 days after FDA receives it unless the agency places the proposed investigation on clinical hold, or on earlier notification from FDA that the study may begin. The study must also have the required Institutional Review Board approval and satisfy other applicable requirements before participants are dosed.

When is an IND required?

An IND is generally required when a sponsor plans a U.S. clinical investigation of an unapproved drug or biological product. An IND may also be required for a study of an approved product if the investigation involves a new indication, route, dose, population or other change that does not meet the applicable exemption criteria.

The correct determination depends on the product, intended investigation and applicable regulations. Sponsors should resolve the question early because an incorrect pathway assumption can affect nonclinical planning, manufacturing strategy, protocol design, budget and timing.

What are the main IND application requirements?

The required order and content of an IND are described in 21 CFR 312.23. The depth of information is not identical for every program. It should reflect the product, modality, phase of development, duration of exposure, route of administration, participant population and risks of the proposed study.

A typical initial IND includes the following content areas:

Administrative and regulatory information

• Cover letter and Form FDA 1571
• Detailed table of contents
• Introductory statement and general investigational plan
• Applicable investigator, financial-disclosure and ClinicalTrials.gov certification forms
• Letters of authorization or cross-references, when information is incorporated from another file

FDA maintains current IND forms and instructions. Sponsors should confirm the current forms, submission standards and product-center requirements rather than relying on an old template.

Investigator's Brochure

The Investigator's Brochure gives investigators a concise, current account of the investigational product and the evidence relevant to its clinical use. It typically addresses the product and formulation, pharmacology, toxicology, pharmacokinetics, prior human experience, anticipated risks and the precautions or monitoring needed in the study. It is a living document that must remain aligned with emerging information.

Clinical protocol and investigator information

The protocol should explain the study objectives, population, inclusion and exclusion criteria, design, dose-escalation approach, dose rationale, treatment duration, safety monitoring, stopping rules and methods for minimizing risk. The level of detail should be appropriate to the phase. The protocol, Investigator's Brochure, informed-consent materials and safety plan should tell a consistent story.

Chemistry, manufacturing and controls

The CMC section should provide enough information to support the identity, quality, purity, strength and stability of the investigational drug used in the proposed study. It addresses the drug substance, drug product, manufacturers, manufacturing and packaging processes, controls, analytical methods, specifications, stability, labeling and, when applicable, placebo information.

For an initial Phase 1 program, FDA regulations recognize that manufacturing knowledge will continue to develop. “Phase appropriate” does not mean incomplete or informal. It means the evidence and controls are proportionate to the proposed exposure and risks while still giving FDA a defensible basis for assessing product quality and participant safety.

Pharmacology and toxicology

The nonclinical package should support the conclusion that the proposed clinical investigation is reasonably safe to begin. Its design depends on the product and clinical plan, but it may include primary and secondary pharmacology, safety pharmacology, pharmacokinetics, toxicokinetics, repeat-dose toxicology, genotoxicity and other studies appropriate to the modality, route and duration of exposure.

FDA expects an integrated interpretation, not only a collection of reports. The submission should connect study findings to the proposed starting dose, escalation plan, eligibility criteria, monitoring strategy and stopping rules. Known uncertainties and potentially relevant safety signals should be explained directly.

Previous human experience and additional information

If the product or a closely related product has been used in humans, the relevant experience should be summarized. Certain products may require additional information related to topics such as abuse potential, radiation exposure, pediatrics or another product-specific concern.

How to prepare an IND application in eight steps

1. Define the proposed clinical use before building the package

Start with the clinical study FDA will review. Clarify the indication, target population, route of administration, dosage form, starting dose, escalation approach, treatment duration, key endpoints and safety controls. These choices determine what the nonclinical and CMC programs must support.

A practical planning document should connect each major clinical decision to its supporting evidence. For example, the starting-dose section should point to the relevant toxicology, pharmacology, exposure and modeling analyses. The clinical formulation and presentation should be traceable to the material used in pivotal nonclinical work, with differences assessed and justified.

If the regulatory pathway or product classification remains uncertain, resolve it before the submission schedule becomes fixed. BioBoston's regulatory strategy and submission services can help sponsors identify the pathway, decision points, risks and evidence needed for an executable development plan.

2. Conduct an integrated IND readiness and gap assessment

An IND readiness assessment should examine regulatory, nonclinical, CMC, clinical, biostatistical, quality and publishing readiness together. Reviewing each function independently can miss the cross-functional inconsistencies that often lead to late rework.

The assessment should answer four practical questions:

• What information is required for the proposed study and product?
• What is complete, in progress, missing or not yet suitable for submission?
• Which gaps could affect participant safety, trigger FDA questions or threaten the filing date?
• Who owns each action, dependency, decision and approval?

The most useful output is not a long issue list. It is a prioritized remediation plan that separates critical-path items from improvements that can be completed later. Assign owners, due dates, evidence needed for closure and escalation routes. This gives leadership a realistic view of readiness and prevents teams from spending equal effort on issues with very different levels of risk.

3. Use the pre-IND meeting to resolve decisions, not to present a general update

A pre-IND meeting is not mandatory, but it can be valuable when the program includes a novel modality, unusual nonclinical approach, complex starting-dose strategy, new manufacturing platform, uncommon endpoint or another issue where early FDA feedback may materially change the plan.

The meeting request and briefing package should focus on decisions. Each question should state the sponsor's proposed approach, summarize the supporting rationale and ask FDA for specific feedback. Questions that are broad, theoretical or already answered in published guidance are less likely to produce actionable direction.

Prepare the team as carefully as the package. Regulatory, nonclinical, CMC, clinical and statistical representatives should understand the proposed positions, likely follow-up questions, alternative approaches and decision authority. BioBoston provides health authority meeting support for meeting strategy, briefing content, rehearsal, participation and follow-up planning.

4. Build a nonclinical argument that supports the exact clinical plan

The nonclinical strategy should be designed backward from the proposed human study. Study species, dose levels, route, schedule, duration, recovery periods, endpoints and exposure characterization should be scientifically justified and relevant to the clinical plan.

Do not leave interpretation until the final summary is drafted. Review emerging findings as an integrated body of evidence and consider how they affect:

• Starting dose and maximum planned exposure
• Dose-escalation increments and observation periods
• Participant eligibility and exclusion criteria
• Clinical laboratory and other safety monitoring
• Dose-interruption, stopping and discontinuation rules
• Risks described in the Investigator's Brochure and informed-consent materials

The starting-dose rationale should make assumptions and uncertainties visible. Depending on the modality and risk profile, the rationale may draw on no-observed-adverse-effect levels, pharmacologically active doses, minimum anticipated biological effect levels, exposure margins, modeling and other scientifically appropriate methods. The method should be selected for the product, not copied from an unrelated program.

5. Develop a phase-appropriate CMC strategy with room to learn

Early development requires balance. The CMC package must be strong enough to support identity, quality, purity, strength, stability and safe clinical use, while recognizing that the process, formulation, methods and specifications may evolve.

Prioritize the elements most relevant to participant safety and consistent clinical supply:

• Clear description and characterization of drug substance and drug product
• Qualified manufacturers and traceable responsibilities
• Manufacturing-process descriptions and controls appropriate to the product
• Specifications and analytical methods supported by available knowledge
• Impurity, microbiological and adventitious-agent controls, as applicable
• Container-closure, storage, shipping and in-use considerations
• Stability information covering the planned clinical-use period
• Comparability or bridging rationale when clinical and nonclinical materials differ

One of the most consequential CMC questions is whether the material used in nonclinical studies adequately represents the material intended for participants. Differences should be identified early, assessed for their potential safety impact and addressed through data, risk assessment, additional testing or an appropriate bridging strategy.

BioBoston's regulatory CMC support can cover strategy, gap assessment, drug-substance and drug-product content, stability planning, specifications, control strategy, authoring and FDA response support.

6. Align the clinical protocol, Investigator's Brochure and safety rationale

FDA reviewers should not have to reconcile different versions of the risk story. The protocol, Investigator's Brochure, nonclinical summary and CMC information should use consistent product descriptions, dose units, exposure assumptions, risk statements and mitigation measures.

Before finalization, run a structured cross-document check that covers:

• Product name, formulation, route and presentation
• Starting dose, escalation limits and maximum exposure
• Known and theoretical risks
• Eligibility criteria and prohibited medications
• Safety assessments and collection schedules
• Stopping, interruption and discontinuation rules
• Adverse-event definitions and reporting pathways
• Investigational-product storage, preparation and accountability

A scientifically sound protocol also has to be operational. Sites must be able to implement its assessments, decision rules and time windows consistently. BioBoston supports clinical trial design and strategy as well as medical writing for regulatory submissions.

7. Control authoring, review and eCTD publishing as one process

Strong technical content can still create review risk if it is difficult to navigate, inconsistent or submitted in the wrong format. Build a content plan that identifies every deliverable, source document, author, reviewer, approver, data cutoff, dependency and publishing date.

Use a review model with defined purposes. Functional reviewers should verify scientific and technical accuracy. Cross-functional reviewers should test consistency across sections. Quality-control review should confirm references, tables, figures, terminology, hyperlinks and lifecycle operations. A senior reviewer who was not immersed in day-to-day authoring should assess whether the complete submission presents a coherent safety argument.

Commercial INDs submitted to CDER or CBER are subject to electronic submission requirements. FDA identifies the Electronic Common Technical Document as the standard format for applications and subsequent submissions. Sponsors should consult FDA's current eCTD requirements and supported versions and reserve enough time for technical validation and correction before the target filing date.

8. Conduct an independent submission-readiness review and prepare for FDA questions

A final readiness review should look at the package from FDA's perspective. The review should identify issues that could prevent an assessment of safety, create contradictions, obscure the dose rationale or make the submission difficult to review.

Useful review questions include:

• Can a reviewer follow the evidence from product characterization and nonclinical findings to the proposed clinical controls?
• Are important uncertainties acknowledged and managed?
• Does the clinical protocol address the safety signals identified elsewhere?
• Is the CMC package sufficient for the proposed phase, duration and exposure?
• Are all tables, figures, datasets and source references internally consistent?
• Are commitments, pending items and future updates clearly identified?
• Has the published sequence passed technical validation?

Submission is not the end of the work. Establish a rapid-response team before filing. Identify the regulatory lead, functional responders, decision makers and document-control process that will handle FDA information requests or a potential clinical-hold issue. Fast answers are useful only when they are accurate, aligned and properly approved.

IND application checklist

Use this high-level checklist to organize an initial readiness review. It is not a substitute for a product-specific regulatory assessment.

Regulatory strategy and governance

• The proposed indication, population, route, formulation and clinical objectives are defined.
• The regulatory pathway and responsible FDA center and review division have been assessed.
• A pre-IND meeting strategy has been completed or the rationale for proceeding without one is documented.
• A cross-functional content plan identifies owners, reviewers, dependencies and decision dates.
• Critical risks and unresolved questions have named owners and escalation paths.

Administrative content

• The cover letter, Form FDA 1571 and table of contents are complete.
• Forms FDA 1572, 3674 and financial-disclosure documents are addressed as applicable.
• The introductory statement and general investigational plan are current and consistent with the protocol.
• Letters of authorization, rights of reference and incorporated information are available and correctly cited.
• Sponsor, U.S. agent, CRO and transferred-obligation information is accurate, as applicable.

CMC readiness

• Drug-substance and drug-product descriptions are complete and consistent.
• Manufacturing sites, processes, controls and responsibilities are accurately described.
• Specifications, analytical methods and batch information support the proposed clinical material.
• Relevant impurities and product-specific safety risks are assessed.
• Available stability information supports the planned storage and clinical-use period.
• Differences between nonclinical and clinical materials have been evaluated and justified.
• Labeling, packaging, shipping and accountability requirements are addressed.

Nonclinical readiness

• The nonclinical program supports the proposed route, schedule, duration and population.
• Pharmacology, pharmacokinetic and toxicology findings are integrated rather than presented in isolation.
• GLP status and any deviations are clearly documented.
• Relevant safety signals and their clinical implications are addressed.
• The starting-dose and exposure rationale is transparent and reproducible.
• Data tables, study narratives and source reports are consistent.

Clinical readiness

• The protocol's objectives, endpoints, population and design are scientifically justified.
• Dose escalation, maximum exposure and decision rules are clear.
• Safety assessments, stopping rules and risk-mitigation measures reflect available evidence.
• The Investigator's Brochure, protocol and informed-consent materials are aligned.
• Investigator qualifications, site information and IRB plans are addressed.
• The study is operationally feasible for sites, laboratories and vendors.

Submission and quality control

• All sections have completed scientific, cross-functional and quality-control review.
• Terminology, abbreviations, dose units, tables, figures and references are consistent.
• Electronic files meet current FDA and eCTD technical requirements.
• Lifecycle operations, hyperlinks and navigation have been validated.
• The sponsor has a controlled response process for FDA questions.
• Post-submission responsibilities and IND maintenance activities have assigned owners.

How long does IND preparation take?

There is no universal IND preparation timeline. A program with mature, aligned data and experienced functional owners may move efficiently through authoring and publishing. A program with unresolved toxicology, stability, manufacturing, dose-selection or protocol issues may need substantially more time.

The best schedule is evidence-based. Build it from the latest required data or decision, then work backward through integrated analysis, authoring, functional review, cross-functional review, approval, publishing and technical validation. Include contingency for findings that affect more than one section.

The FDA's 30-day period begins after the agency receives the IND. It is not the total time required to prepare the application. During that review period, the sponsor should remain ready to answer questions. Unless FDA provides earlier notification, the clinical investigation cannot begin before the IND goes into effect, and all other requirements, including IRB approval, must also be satisfied.

Common IND preparation mistakes that create avoidable risk

Treating the IND as a collection of independent sections

FDA reviews the relationship between the evidence and the proposed study. A polished CMC section does not compensate for a protocol that describes a different formulation, and a strong toxicology package does not help if its findings are not reflected in clinical monitoring and stopping rules.

Locking the filing date before understanding the critical path

A target date can create focus, but an unsupported date can encourage teams to hide uncertainty or postpone difficult decisions. Confirm the data dependencies and the time required to interpret them before committing to the final authoring and publishing schedule.

Using “phase appropriate” as a reason to leave CMC risks unresolved

FDA permits development-stage flexibility, but the package still needs to support product quality and safe clinical use. Product-specific risks, uncertain impurity profiles, insufficient stability or poorly understood differences between batches can remain important even in Phase 1.

Presenting data without a clear interpretation

Reviewers need to understand what the findings mean for human dosing and risk management. Summaries should identify key results, limitations, uncertainties and the resulting clinical controls. Selective presentation or overstated conclusions can weaken credibility.

Starting cross-functional review too late

If integration begins only after sections are considered final, every inconsistency becomes a late change across several documents. Schedule focused alignment reviews while the content is still developing, especially for dose rationale, product description, safety risks and clinical monitoring.

Leaving publishing and technical validation until the final days

Broken links, incorrect lifecycle operations, invalid files and navigation problems can delay a technically complete package. Run rolling quality checks and test the planned eCTD sequence before the final deadline.

Planning for submission but not for the active IND

Once the IND is in effect, sponsor obligations continue. Protocol amendments, information amendments, safety reporting, annual reports, Investigator's Brochure updates, CMC changes and ongoing oversight need controlled processes and accountable owners.

How BioBoston Consulting supports IND preparation and submission

IND programs often need senior expertise across several disciplines at the same time, but not every sponsor needs to build a large permanent department. BioBoston Consulting can provide focused support for a defined gap or an integrated team from strategy through submission and IND maintenance.

Our network includes more than 450 life sciences consultants worldwide. Many bring more than 20 years of industry experience, including former FDA investigators and senior professionals across regulatory affairs, CMC, nonclinical development, clinical development, biostatistics, quality and medical writing.

Support can include:

• IND readiness assessment and prioritized remediation plan
• Regulatory pathway and pre-IND meeting strategy
• Meeting request, briefing package and rehearsal support
• Nonclinical strategy and integrated summary review
• Starting-dose and clinical-risk rationale coordination
• Phase-appropriate CMC strategy, content and gap remediation
• Clinical protocol and Investigator's Brochure development or review
• Cross-functional content planning, authoring and quality control
• eCTD submission management and readiness review
• FDA information-request and clinical-hold response support
• Ongoing amendments, annual reports and fractional regulatory leadership

Engagements can be structured around a focused deliverable, milestones, hourly support or a longer-term retainer. That flexibility allows a sponsor to start with the most urgent readiness issue and scale support as the program moves into the clinic.

Frequently asked questions about IND applications

What are the three main technical areas of an IND application?

FDA describes three broad technical areas: animal pharmacology and toxicology information, manufacturing information, and clinical protocols with investigator information. The full IND also includes administrative forms, the general investigational plan, the Investigator's Brochure, previous human experience and other information required by 21 CFR 312.23.

How long does FDA take to review an initial IND?

An IND generally goes into effect 30 days after FDA receives it unless FDA notifies the sponsor that the investigation is on clinical hold. FDA may also notify the sponsor earlier that the investigation may begin. The study cannot start until the IND is in effect and applicable requirements such as IRB approval have been satisfied.

Is a pre-IND meeting required?

No. A pre-IND meeting is optional. It can be especially useful when early FDA feedback could change a major nonclinical, CMC or clinical decision. The value depends on the quality of the sponsor's questions, supporting rationale and readiness to act on the feedback.

What is the difference between IND-enabling studies and the IND application?

IND-enabling work is the scientific and operational program that generates the evidence needed to support first-in-human testing. It may include pharmacology, toxicology, bioanalytical work, manufacturing development, analytical testing, stability and clinical planning. The IND application is the regulated submission that organizes and interprets the relevant evidence for FDA review.

Does every IND require the same studies and level of detail?

No. Requirements depend on the investigational product, modality, route, indication, population, duration of exposure, clinical phase and identified risks. FDA regulations also recognize that the amount of CMC and protocol detail can vary by development stage. Product-specific guidance and early agency interaction may be important.

Can an IND be submitted in eCTD format?

Yes. FDA identifies eCTD as the standard format for submissions to CDER and CBER, and commercial IND applications are subject to electronic submission requirements. Noncommercial INDs may be treated differently. Sponsors should verify the current standards, supported eCTD versions and exemptions on FDA's website before filing.

What happens after an IND goes into effect?

The sponsor's responsibilities continue throughout the investigation. Depending on the program, these can include protocol and information amendments, expedited safety reports, annual reports, Investigator's Brochure updates, CMC updates, investigator oversight, monitoring and responses to FDA communications.

Can BioBoston support only one part of an IND?

Yes. BioBoston Consulting can support a focused need, such as a readiness assessment, pre-IND briefing package, CMC gap, nonclinical summary, clinical protocol, medical-writing review or FDA response. We can also assemble a cross-functional team for end-to-end preparation and ongoing IND maintenance.

This article is for general educational purposes and does not replace product-specific regulatory, scientific or legal advice. FDA requirements and guidance can change, and sponsors should confirm the current requirements applicable to their product and investigation.